Insmed Incorporated

NasdaqGS:INSM Stock Report

Market Cap: US$37.5b

Insmed Management

Management criteria checks 3/4

Insmed's CEO is Will Lewis, appointed in Sep 2012, has a tenure of 13.33 years. total yearly compensation is $10.94M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $71.34M. The average tenure of the management team and the board of directors is 6.4 years and 9.7 years respectively.

Key information

Will Lewis

Chief executive officer

US$10.9m

Total compensation

CEO salary percentage7.40%
CEO tenure13.3yrs
CEO ownership0.2%
Management average tenure6.4yrs
Board average tenure9.7yrs

Recent management updates

Recent updates

Insmed Impresses With Pulmonary Portfolio, But Still Lacks Remedy To Turn A Profit

Dec 17

Insmed Incorporated's (NASDAQ:INSM) Shares Climb 40% But Its Business Is Yet to Catch Up

Jun 11
Insmed Incorporated's (NASDAQ:INSM) Shares Climb 40% But Its Business Is Yet to Catch Up

Here's Why Insmed Incorporated's (NASDAQ:INSM) CEO May Have Their Pay Bumped Up

May 08
Here's Why Insmed Incorporated's (NASDAQ:INSM) CEO May Have Their Pay Bumped Up

Insmed: Poised For Transformation Beyond ARIKAYCE

Apr 25

Insmed Incorporated's (NASDAQ:INSM) Business Is Yet to Catch Up With Its Share Price

Apr 15
Insmed Incorporated's (NASDAQ:INSM) Business Is Yet to Catch Up With Its Share Price
User avatar

Brensocatib's 2025 Launch Will Transform Bronchiectasis Care

Anticipated U.S. and international launches of brensocatib are key catalysts for significant revenue growth and new market penetration.

Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity

Feb 07

Is Insmed (NASDAQ:INSM) Using Debt Sensibly?

Jan 20
Is Insmed (NASDAQ:INSM) Using Debt Sensibly?

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Nov 20

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Aug 28

CEO Compensation Analysis

How has Will Lewis's remuneration changed compared to Insmed's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$1b

Jun 30 2025n/an/a

-US$1b

Mar 31 2025n/an/a

-US$1b

Dec 31 2024US$11mUS$810k

-US$914m

Sep 30 2024n/an/a

-US$864m

Jun 30 2024n/an/a

-US$803m

Mar 31 2024n/an/a

-US$747m

Dec 31 2023US$10mUS$780k

-US$750m

Sep 30 2023n/an/a

-US$724m

Jun 30 2023n/an/a

-US$696m

Mar 31 2023n/an/a

-US$547m

Dec 31 2022US$8mUS$735k

-US$482m

Sep 30 2022n/an/a

-US$434m

Jun 30 2022n/an/a

-US$416m

Mar 31 2022n/an/a

-US$438m

Dec 31 2021US$7mUS$710k

-US$435m

Sep 30 2021n/an/a

-US$424m

Jun 30 2021n/an/a

-US$375m

Mar 31 2021n/an/a

-US$319m

Dec 31 2020US$6mUS$660k

-US$294m

Sep 30 2020n/an/a

-US$245m

Jun 30 2020n/an/a

-US$242m

Mar 31 2020n/an/a

-US$247m

Dec 31 2019US$7mUS$641k

-US$254m

Compensation vs Market: Will's total compensation ($USD10.94M) is about average for companies of similar size in the US market ($USD13.25M).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.

CEO

Will Lewis (56 yo)

13.3yrs
Tenure
US$10,943,571
Compensation

Mr. William H. Lewis, also known as Will, J.D. M.B.A. serves as an Independent Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January 2024. He has been Chief Executive Officer and...

Leadership Team

NamePositionTenureCompensationOwnership
William Lewis
President13.3yrsUS$10.94m0.19%
$ 71.3m
Sara Bonstein
Chief Financial Officer6yrsUS$4.01m0.00071%
$ 266.5k
Roger Adsett
Chief Operating Officer6.2yrsUS$4.26m0.019%
$ 7.3m
Martina Flammer
Chief Medical Officer6.1yrsUS$4.11m0.0098%
$ 3.7m
Brian Kaspar
Chief Scientific Officerno datano datano data
Bryan Dunn
Vice President of Investor Relationsno datano datano data
Michael Smith
Chief Legal Officer & Corporate Secretary4.5yrsno data0.027%
$ 10.0m
Claire Mulhearn
Vice President of Corporate Communicationsno datano datano data
S. Schaeffer
Chief People Strategy Officer13yrsUS$2.66m0.020%
$ 7.3m
Eugene Sullivan
Chief Product Strategy Officer8.7yrsUS$1.69mno data
Neil Hughes
GM & Head of Europe6.6yrsno datano data
Kevin Mange
Head of Clinical Developmentno datano datano data
6.4yrs
Average Tenure
56yo
Average Age

Experienced Management: INSM's management team is seasoned and experienced (6.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Lewis
President13.3yrsUS$10.94m0.19%
$ 71.3m
David W. McGirr
Independent Director12.3yrsUS$410.00k0.043%
$ 16.3m
Melvin Sharoky
Independent Director24.7yrsUS$402.50k0.12%
$ 46.6m
David Brennan
Lead Independent Director11.7yrsUS$435.00k0.057%
$ 21.4m
Clarissa Desjardins
Independent Director6.2yrsUS$405.00k0.030%
$ 11.4m
Elizabeth Anderson
Independent Director7.2yrsUS$400.00k0.025%
$ 9.4m
Leo Lee
Independent Director7.7yrsUS$407.50k0.023%
$ 8.7m
Carol Schafer
Independent Director5.8yrsUS$405.00k0.027%
$ 10.3m
9.7yrs
Average Tenure
64.5yo
Average Age

Experienced Board: INSM's board of directors are considered experienced (9.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/10 08:44
End of Day Share Price 2026/01/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insmed Incorporated is covered by 39 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargBaird
Anita DushyanthBerenberg
Jason ZemanskyBofA Global Research